Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Journal of Clinical Pharmacology|September 11, 2019
Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver MicrosomesJustine Badée, Nahong Qiu, Abby C Collier, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|June 29, 2017
In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymesToshito Nakagawa, Stephen Fowler, Kenji Takanashi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 3, 2020
Application of the Extended Clearance Classification System (ECCS) in Drug Discovery and Development: Selection of Appropriate In Vitro Tools and Clearance PredictionKenichi Umehara, Carina Cantrill, Matthias Beat Wittwer, et al.
Pharmaceutical Research|February 23, 2012
Mass spectrometry-based quantification of CYP enzymes to establish in vitro/in vivo scaling factors for intestinal and hepatic metabolism in beagle dogAki T Heikkinen, Arno Friedlein, Jens Lamerz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 30, 2021
Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 EnzymesRyan H Takahashi, William F Forrest, Alexander D Smith, et al.
Journal of Clinical Pharmacology|December 28, 2019
Coexpression of Human Hepatic Uridine Diphosphate Glucuronosyltransferase Proteins: Implications for Ontogenetic Mechanisms and Isoform CoregulationYuejian Liu, Justine Badée, Ryan H Takahashi, et al.
Archives of Toxicology|August 4, 2016
Humanizing the zebrafish liver shifts drug metabolic profiles and improves pharmacokinetics of CYP3A4 substratesKar Lai Poon, Xingang Wang, Ashley S Ng, et al.
European Journal of Drug Metabolism and Pharmacokinetics|September 8, 2021
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-MakingNassim Djebli, Vincent Buchheit, Neil Parrott, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 16, 2014
A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposureStephen Fowler, Heidemarie Kletzl, Moshe Finel, et al.
BMJ Open|January 26, 2017
MyAirCoach: the use of home-monitoring and mHealth systems to predict deterioration in asthma control and the occurrence of asthma exacerbations; study protocol of an observational studyPersijn J Honkoop, Andrew Simpson, Matteo Bonini, et al.
Pageof 8